2020
Coronavirus disease 2019 and neurodegenerative disease: what will the future bring?
McAlpine LS, Fesharaki-Zadeh A, Spudich S. Coronavirus disease 2019 and neurodegenerative disease: what will the future bring? Current Opinion In Psychiatry 2020, 34: 177-185. PMID: 33395100, PMCID: PMC7924921, DOI: 10.1097/yco.0000000000000688.Peer-Reviewed Original ResearchConceptsCoronavirus disease 2019Multiple sclerosisParkinson's diseaseNeurodegenerative diseasesAlzheimer's diseaseDisease 2019High riskCOVID-19Heart/lung diseaseHigh-risk comorbid conditionsHospitalized COVID-19 patientsAltered mental statusCOVID-19 patientsMS patientsSuch patientsComorbid conditionsNeurological symptomsPoor outcomeLung diseaseMental statusAdvanced ageSevere diseasePatientsBetter outcomesViral infection
2006
Defining and Evaluating HIV-Related Neurodegenerative Disease and Its Treatment Targets: A Combinatorial Approach to Use of Cerebrospinal Fluid Molecular Biomarkers
Gisslen M, Hagberg L, Rosengren L, Brew BJ, Cinque P, Spudich S, Price RW. Defining and Evaluating HIV-Related Neurodegenerative Disease and Its Treatment Targets: A Combinatorial Approach to Use of Cerebrospinal Fluid Molecular Biomarkers. Journal Of Neuroimmune Pharmacology 2006, 2: 112-119. PMID: 18040834, DOI: 10.1007/s11481-006-9035-1.Peer-Reviewed Original ResearchConceptsCNS HIV infectionAIDS dementia complexHIV infectionBrain injuryTreatment targetsCentral nervous system infectionNeurodegenerative diseasesSystemic HIV infectionComorbidities of patientsNervous system infectionAdjuvant treatment approachesCerebrospinal fluid markersRational trial designIntrathecal immunoactivationSystem infectionDementia complexAvailable treatmentsClinical trialsFluid markersTrial designTreatment approachesClinical practiceExperimental therapeuticsPatientsInfection